20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in normal renal function
HD                     :Not dialysed. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Not dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known
ADMINISTRATION
Reconstition
3 mL of the supplied diluent (absolute ethanol) then add 27 mL of sterile water for injection
This solution may be further diluted with sodium chloride 0.9% or glucose 5% for injection
Route
IV
Rate of Administration
Administer by IV drip over a period of 1–2 hours
Comments
Therapy should not be repeated before 6 weeks
Can further dilute the reconstituted solution with 500 mL of sodium chloride 0.9% or glucose 5%
OTHER INFORMATION
Renal abnormalities, e.g. a decrease in kidney size: progressive azotaemia and renal failure have been reported in patients receiving large cumulative doses after prolonged therapy
Partially metabolised to active species by liver microsomal enzymes, which have a long T½. It is thought that the antineoplastic activity may be due to metabolites. Approximately 30% of a dose is excreted in the urine after 24 hours, and 60–70% of the total dose after 96 hours. About 10% is excreted as respiratory CO2. Terminal half-life of the metabolites are about 1 hour.